Market Reports

Catalent signs development deal with Ethicann for new fast-dissolve cannabinoid treatment

Catalent and Canadian/US cannabinoid drug therapy company Ethicann Pharmaceuticals have executed a development and license agreement that will use Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology

Host cell protein analysis: strategies to improve sensitivity and reproducibility

Given that the US FDA approved 25 new cellular and gene therapy products in 2022, gene-based vaccines and therapeutics have now entered the mainstream pharmaceutical industry. However, the rising interest in gene-based strategies puts pressure on manufacturers to demonstrate optimum efficacy and safety

Manufacturing Chemist LIVE 2023: Expert Speakers Wanted

Previous years have included presentations from the likes of NASA, AstraZeneca, GSK, CMAC and we are now looking for 2023's experts

Cell and gene therapies: on the brink of commercialisation

With their one-and-done potential and pinpoint targeting capability, cell and gene therapies (CGTs) offer huge promise in the fight against a range of previously untreatable diseases. Yet, investment in this sector is not taken lightly. Typically, developers must invest billions of dollars in therapies that might take 10 years to reach the market as they battle the odds against high failure rates

Inspiration from unexpected places

How pharmaceutical companies can learn from advances in nicotine delivery

Overcoming hurdles in the biopharmaceutical pipeline with advanced analytics

In conversation with Nick Pittman and Magnus Wetterhall, both Global Marketing Managers, Bioprocessing, at Waters Corporation, Dr Kevin Robinson explored some of the big issues associated with manufacturing biologics, how they can be overcome and what Waters is doing to help scientists expedite the process of developing new therapies for patients in need

Treating infection with precise medicine may prevent our next pandemic

Antimicrobial resistance (AMR) is a grave concern that the scientific and medical community have been warning the public about for decades. There have been no new antibiotics for 35 years and no truly effective incentive for drug makers to develop them, making this threat even more urgent. As the COVID-19 pandemic demonstrated, preparedness could save countless lives and the world’s economy

Optimising coating process parameters and formulation concepts for functional taste-masking during continuous manufacturing

This article describes work done to optimise the coating process parameters (spray rate, inlet air temperature, inlet airflow), formulation and functionality of a taste-masking coat for oral solid dosage forms during continuous production

Dissolution testing: an established technique driving advances in drug delivery

This article introduces dissolution testing and highlights its ability to support modern formulation challenges. Pharmacopoeial methods are discussed with reference to specific apparatuses and method parameters. Dissolution testing equipment from Copley Scientific is showcased to illustrate the performance and productivity that are accessible with well-designed, cost-effective solutions

COVID-19: focusing attention on the next transformation in healthcare

The lightning-fast global spread of the Omicron variant of COVID-19 was a painful reminder that the only way to protect against the disease is vaccination on a global level. At the same time, South African researchers’ quick identification and analysis of Omicron demonstrated the strength and interconnectedness of the international science community, with critical data rapidly passed to those who were best able to mount a response

Manufacturing Chemist LIVE 2022 in review (part I)

Taking a front row seat during the two-day pharmaceutical conference in Birmingham, UK, Dr Kevin Robinson reports on what’s new, emerging and exciting in the world of drug delivery and beyond

Native mass spectrometry as a drug discovery engine

Using mass spectrometry to characterise and screen large intact protein targets, captured directly in their native state, is making waves as a differentiated approach to hit finding in drug discovery, explains Dr Jonathan T.S. Hopper, founder and VP of Platforms at OMass Therapeutics

Transforming tomorrow

Shaping the future with better processes, GEA has responded to the impact that digitalisation is having on the pharmaceutical manufacturing industry and pioneered a suite of virtual technologies that improve the customer experience

Chemistry meets biology: an integrated approach to developing and manufacturing medicines of the future

Until recently, chemists and biologists rarely needed to collaborate to develop a new large molecule drug, reports Chris Conway, President, Research and Development, Curia

Closing the gap between biotherapies and their quality control

NGS-based biosafety tests are giving the biomanufacturing industry a facelift

Droplet microfluidics: leveraging the untapped potential of single-cell research and high-throughput screening

The age of personalised medicine requires modern tools. Recent research breakthroughs such as the meteoric rise of CRISPR technology and the emergence of single-cell sequencing have clearly shown a vast untapped potential in the life sciences, reports Juozas Nainys, CEO of Droplet Genomics

A smart approach to ready-to-use drug containment solutions

At a time when global healthcare providers are coming under previously unknown levels of pressure, their suppliers need to react with greater speed and flexibility to meet demand without compromising patient safety

Influence of material and capsule filling process on DPI aerosolisation performance

The effect of capsule filling parameters on emitted dose and fine particle fraction by a DPI was investigated using a benchtop capsule filling device. Compression was the parameter that affected weight and emitted fraction the most, whereas the type of coarse lactose seems to influence the fine particle fraction

Bringing biotech to the Baltics: the rise of Lithuania

Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a still-unsaturated market. Dr Kevin Robinson spoke with the country’s Minister for Economy and Innovation, Aušrinė Armonaitė, to find out more

Driving biotherapeutic development with advanced molecule characterisation

Evaluating and characterising complicated protein structures and the therapeutic activity of advanced biotherapeutic molecules requires sensitive analytical technologies and informatics systems. As such, executing accurate, analytical assessments of complex biological molecules in a commercial laboratory setting can be challenging, explains Eliza Lee, Lead Scientist Analytics, Samsung Biologics

Deciding on a chemistry, manufacturing and control strategy for biologic development

Khanh Ngo Courtney from Avomeen discusses what biopharmaceutical companies should keep in mind as they embark on their CMC journey

The new regulatory world for medical devices

Establishing an effective compliance strategy now ahead of the 2022 IVDR legislation is critical — because there’s more to come

Manufacturing vaccines, digital twins and lessons learned: part I

Using a digital replica of the manufacturing process, the pharmaceutical industry is exploring the ability of virtual technology to improve the efficiency and agility of the production chain and expedite time-to-market

Using ddPCR to accurately quantify AAV viral titre and integrity

Gene therapy is primed to become the next major development in medicine and bring relief to patients living with diseases ranging from haemophilia to Alzheimer’s disease, write Mark White, Associate Director of Biopharma Product Marketing, and Marwan Alsarraj, Biopharma Segment Manager, Bio-Rad

Trending Articles

  1. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  2. Reading and understanding vendor-supplied tablet drawings Understanding the tablet drawings supplied by tooling vendors is a meaningful way to learn more about your product, reports John Norman, Technical Service Representative, Natoli Engineering Company
  3. Native mass spectrometry as a drug discovery engine Using mass spectrometry to characterise and screen large intact protein targets, captured directly in their native state, is making waves as a differentiated approach to hit finding in drug discovery, explains Dr Jonathan T.S. Hopper, founder and VP of Platforms at OMass Therapeutics
  4. How predictive and preventive maintenance can optimise your pharmaceutical manufacturing line With a tailored approach to maintenance, manufacturers can extend their system’s lifetime and anticipate time-consuming breakdowns before they happen
  5. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin

Upcoming event

Cleanroom Technology Conference UK

21–22 May 2025 | Conference and Exhibition | Birmingham, UK See all